Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.81 |
| ▸ | GBA2 | Q9HCG7 | 13/20 | 0.59 |
| ▸ | GBA1 | P04062 | 8/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | UGCG | Q16739 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18114674 | 1.00 | MGAM (0.81) | MGAMGBA2GBA1GAAUGCG | |
| SCHEMBL15593095 | 1.00 | MGAM (0.81) | MGAMGBA2GBA1GAAUGCG | |
| SCHEMBL15593233 | 1.00 | MGAM (0.81) | MGAMGBA2GBA1GAAUGCG | |
| SCHEMBL15593092 | 1.00 | MGAM (0.81) | MGAMGBA2GBA1GAAUGCG | |
| SCHEMBL15593099 | 1.00 | MGAM (0.81) | MGAMGBA2GBA1GAAUGCG | |
| SCHEMBL19557577 | 1.00 | MGAM (0.81) | MGAMGBA2GBA1GAAUGCG | |
| SCHEMBL3327948 | 1.00 | MGAM (0.81) | MGAMGBA2GBA1GAAUGCG | |
| SCHEMBL15593235 | 1.00 | MGAM (0.81) | MGAMGBA2GBA1GAAUGCG | |
| SCHEMBL19557628 | 1.00 | MGAM (0.81) | MGAMGBA2GBA1GAAUGCG | |
| SCHEMBL15598937 | 0.98 | MGAM (0.85) | MGAMGBA2GBA1GAAUGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210082-B1 | LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS | UNIV OXFORD (GB) | 2008-01-02 | — | — | EP | claimed |
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| US-9089515-B2 | Long chain N-alkyl compounds and oxa-derivatives thereof | THOMAS JEFFERSON UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2014032188-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-7816560-B1 | Long chain n-alkyl compounds and oxa-derivatives thereof | THOMAS JEFFERSON UNIVERSITY (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100137365-A1 | Long chain N-alkyl compounds and oxa-derivatives thereof | THOMAS JEFFERSON UNIVERSITY | 2010-06-03 | — | — | US | disclosed |
| EP-1210082-B1 | LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS | UNIV OXFORD (GB) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | MGAM 36/4885GBA2 5/4885GBA1 3/4885 |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | MGAM 40/4885GBA2 44/4885GBA1 25/4885 |
| US-20100137365-A1 | Long chain N-alkyl compounds and oxa-derivatives thereof | OXA1L, OTC, PAICS | MGAM 4389/4885GBA2 2830/4885GBA1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.